Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97353
Title:
Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.
Authors:
Renninson, J; Baker, Bartrum W; McGown, Alan T; Murphy, D; Norton, John D; Fox, Brian W; Crowther, Derek
Abstract:
Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.
Affiliation:
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. 1994, 69 (3):609-12 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Mar-1994
URI:
http://hdl.handle.net/10541/97353
PubMed ID:
8123498
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRenninson, Jen
dc.contributor.authorBaker, Bartrum Wen
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorMurphy, Den
dc.contributor.authorNorton, John Den
dc.contributor.authorFox, Brian Wen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-04-26T08:33:03Z-
dc.date.available2010-04-26T08:33:03Z-
dc.date.issued1994-03-
dc.identifier.citationImmunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. 1994, 69 (3):609-12 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8123498-
dc.identifier.urihttp://hdl.handle.net/10541/97353-
dc.description.abstractApproximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.en
dc.language.isoenen
dc.subjectCancer DNAen
dc.subjectCancer Stagingen
dc.subjectOvarian Canceren
dc.subject.meshBase Sequence-
dc.subject.meshCodon-
dc.subject.meshDNA Primers-
dc.subject.meshDNA, Neoplasm-
dc.subject.meshExons-
dc.subject.meshFemale-
dc.subject.meshGenes, p53-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshMolecular Sequence Data-
dc.subject.meshNeoplasm Staging-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPoint Mutation-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshTumor Suppressor Protein p53-
dc.titleImmunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.